Rick Simpson Oil (RSO) in Louisa County, Iowa: The Complete Guide by OilWell Cannabis

If you’re in Louisa County searching for honest answers about Rick Simpson Oil, you’ve found the most thoroughly documented resource available. We’re OilWell Cannabis, and we built this guide specifically for folks in Wapello, Columbus Junction, Morning Sun, and every corner of Louisa County who deserve real science, not marketing hype. Whether you’re dealing with chronic pain from years on the farm, supporting a loved one through cancer treatment in Muscatine or Burlington, or a veteran near the Mississippi River grappling with PTSD, this is everything we know—sourced from peer-reviewed research, third-party lab testing, and our own decade of formulation work. No snake oil. No false hope. Just the facts, tailored to Louisa County’s reality.

Understanding Rick Simpson Oil: The History Louisa County Needs to Know

Who Was Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or researcher—he was a power engineer and maintenance worker, a blue-collar tradesman whose cannabis advocacy began after the medical system failed him. In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications prescribed either didn’t help or made things worse. Cannabis provided relief, but when he asked his physician about it, the request was refused .

Simpson’s interest deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC reportedly slowed or shrank tumors in mice. That study—originally intended to show harm—became foundational to Simpson’s advocacy, though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. No independent medical verification, biopsy confirmation, or clinical follow-up has ever been published in a peer-reviewed source. This personal experience became the origin story of Rick Simpson Oil .

Important context for Louisa County readers: Simpson’s account is personal testimony, not medical evidence. What matters for our community is that his story—fueled by desperation when doctors had no answers—mirrors the experience of many Louisa County families who’ve driven the 50 miles to Iowa City or the 40 miles to Davenport, only to hear there are no more options. His story is historically significant as the catalyst for a global movement, but it cannot be evaluated as clinical proof.

The Crusade: Spreading the Oil Across Borders and Communities

After 2003, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free—no charge, no profit—to cancer patients and others in his community. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, and insomnia .

His story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical interests. Distributed freely online, it became one of the most widely shared cannabis advocacy films—foundational for many, including some in Louisa County who first learned about RSO through online health communities .

But Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson left Canada for Europe, living in Croatia and later the Netherlands, continuing his advocacy from abroad .

In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his online platform .

Throughout his career, Simpson maintained that cannabis oil—particularly high-THC oil made his way—could cure cancer and many other diseases. He claimed pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect financial interests. He framed his work as fighting institutional corruption .

Important context for Louisa County: Simpson’s conspiratorial worldview reflects distrust shared by many in early cannabis advocacy. In Louisa County, where agricultural communities have seen consolidation hurt small farmers and pharmaceutical marketing has sometimes overshadowed local health solutions, some residents may recognize that skepticism. Our goal is to acknowledge that perspective while grounding every claim in verifiable science.

The Traditional RSO Protocol: 60 Grams Over 90 Days

Simpson’s core recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. This was his cancer treatment protocol, though he recommended it for other conditions too .

Goal: 60 grams of high-THC cannabis oil over ~90 days.

Titration Schedule:

• Week 1: Start with a dose about half a grain of dry rice—roughly 10-15 mg of oil—three times daily (morning, afternoon, before bed). Total daily intake: ~30-45 mg.
• Weeks 2-5: Double the dose every four days to build THC tolerance gradually. By the end of this period, target ~1 gram (1,000 mg) of oil per day, divided into three roughly equal doses.
• Weeks 5-12: Maintain ~1 gram per day (three doses of ~333 mg each) until all 60 grams are consumed.

Administration Methods:

• Primary—oral: Place dose under the tongue (sublingual) or swallow. Simpson considered this most important for systemic absorption and internal cancers.
• Secondary—topical: For skin cancers and external lesions, apply oil directly, cover with a bandage, and change every 3-4 days. He combined topical with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson didn’t recommend smoking or vaporizing as primary treatment, though he acknowledged inhalation for immediate symptom relief (pain, nausea).

Tolerance and Psychoactive Effects:

• Simpson claimed patients develop significant THC tolerance within 3-4 weeks of consistent dosing.
• He considered euphoric, sedating, or disorienting effects minor and temporary, urging patients not to let the high discourage continuation.
• He recommended initial doses at night to sleep through the most intense psychoactive effects.
• He warned against driving or operating machinery during titration and advised informing family members what to expect.

Post-Protocol Maintenance: After completing 60 grams, Simpson recommended ~1-2 grams of oil per month indefinitely, considering this ongoing low-dose maintenance important for long-term health and cancer prevention.

Dietary and Lifestyle: Simpson advocated reducing sugar, avoiding processed foods, and improving overall nutrition, though his dietary advice was secondary and general.

Important Context for Evaluating This Protocol:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific 60-gram/90-day protocol for any condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, patients consumed ~1 gram of high-THC oil daily. Assuming 60-90% THC, this translates to ~600-900 mg of delta-9 THC per day—far exceeding anything studied clinically. For context, FDA-approved dronabinol is typically dosed at 2.5-20 mg per day.
• Real risks at these doses. Consuming 600-900 mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary cancer treatment—potentially in place of proven therapies—introduces harm beyond the oil itself.

What Traditional RSO Was: The Product

Traditional RSO was defined by Simpson’s method and materials, not lab specifications.

Source Material: High-THC, indica-dominant cannabis strains. No strain standardization—starting material varied by availability and growing season.

Extraction Solvent: Originally naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other toxic or carcinogenic compounds. Incomplete solvent purging leaves potentially harmful residues.

Extraction Process:

1. Dry cannabis placed in a bucket
2. Covered with solvent and agitated to dissolve cannabinoids
3. Filtered through cheesecloth into collection vessel
4. Repeated with fresh solvent
5. Combined solvent washes placed in rice cooker
6. Solvent evaporated at relatively low heat (sufficient to decarboxylate THCa into THC and destroy most terpenes)
7. Thick, dark oil remained
8. Transferred to oral syringes

Appearance: Nearly black, thick, tar-like, sticky oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid Profile: Primarily decarboxylated delta-9 THC (60-90% estimated). Minor cannabinoids (CBD, CBN, CBC, CBG) present at natural ratios but uncontrolled, unmeasured, never lab-verified.

Terpene Content: Minimal to none. Solvent extraction and high-heat evaporation stripped terpenes.

Standardization and Testing: None. Every batch differed. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual Solvent Risk: Significant. Naphtha and isopropyl alcohol are not food-grade. Incomplete purging is difficult to verify without lab testing.

Simpson’s Claims vs. The Evidence: What Louisa County Needs to Understand

Simpson claimed RSO could cure cancer and many diseases. He was adamant and consistent throughout his advocacy career .

What Simpson Was Not: Not a scientist, physician, pharmacologist, or researcher. No formal training in medicine, oncology, pharmacology, or clinical research methodology. Never designed, conducted, funded, or published a clinical trial. Never submitted results to peer review. His evidence base: personal experience, self-reported patient outcomes, informal testimonials—no controls, no independent verification, no imaging confirmation, no long-term follow-up, no blinding.

What the Preclinical Literature Shows:

• In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal model studies show some tumor-growth inhibition in mice and rats .
• These findings generate legitimate scientific interest and ongoing research.

What the Preclinical Literature Does NOT Show:

• Findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast.
• No human clinical trial has demonstrated RSO or any cannabis oil cures cancer.
• Small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims .

Institutional Positions:

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis or cannabis oil as cancer treatment .
• U.S. Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid-related products: Epidiolex (CBD) for certain seizure disorders; dronabinol/nabilone (synthetic THC analogues) for chemo-related nausea and AIDS-related wasting [1].
• Health Canada: Never approved RSO or cannabis oil as cancer cure.
• NCCIH: Strongest cannabinoid evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite/weight-loss—not cancer cure [1].

What Simpson Got Right: He drew attention to cannabinoids as serious biomedical research when most of the world ignored or suppressed it. His advocacy helped create political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and “RSO” remains the most recognized name for full-spectrum cannabis extract .

What He Overstated: The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature.

For Louisa County families facing cancer: The nearest major cancer centers are the University of Iowa Holden Comprehensive Cancer Center in Iowa City (about 50 miles north) and Genesis Cancer Care Institute in Davenport (about 40 miles northwest). These facilities provide proven treatments. RSO education should complement medical care, not replace it.

Traditional RSO vs. Modern Formulated RSO: Why It Matters in Louisa County

Dimension	Traditional RSO	OilWell Formulated RSO
Source Material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction Method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid Profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene Content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab Testing	Not available or performed	Full panel testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbial contaminants
Residual Solvents	Significant risk with naphtha	Controlled and tested
Dosing Precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product Formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa Preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence Approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge From Traditional RSO

Our formulations depart from traditional RSO in deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60-90% of total cannabinoid content. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoids across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects broader cannabinoid research rather than single-compound dominance.

• Product format innovation. Simpson envisioned only one format: oral oil from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent Safety and Extraction Evolution: Critical for Iowa DIY Makers

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging is difficult to verify without analytical chemistry equipment, leaving potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography.

This evolution connects directly to product-quality discussion in our GENERAL KNOWLEDGE section, which emphasizes that product quality matters as much as molecule identity—labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

For Louisa County residents considering DIY RSO: The open-source formula we publish later in this guide uses safe, food-grade ingredients. If you’re in rural Louisa County near Fredonia or Columbus City, with limited access to professional products, our published recipe lets you make your own version safely rather than risking naphtha contamination.

The Decarboxylation Question: Why THCa Matters for Louisa County

Traditional RSO was fully decarboxylated. The heat of solvent evaporation (60-80°C for naphtha, ~82°C for isopropyl alcohol) converted essentially all THCa into delta-9 THC, losing acidic cannabinoids as distinct compounds.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is intentional, informed by THCa evidence showing potential non-psychoactive bioactivity via COX-2 inhibition and PPARγ agonism that is lost when THCa converts to THC [12].

Louisa County practical application: This means our product can function as non-psychoactive anti-inflammatory (used raw) for daytime farm work or as full-potency psychoactive cannabinoid medicine (after home decarboxylation) for nighttime relief—entirely at your discretion.

Terpene Loss in Traditional RSO vs. Our Live Terpene Profile

Terpenes are volatile aromatic compounds with low boiling points (21-157°C). Traditional RSO’s solvent extraction and high-heat evaporation stripped terpenes, making it a cannabinoid-only product despite being derived from terpene-rich plants.

Our formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile in our GENERAL KNOWLEDGE section. The entourage-effect literature [20][29] provides theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

For Louisa County’s agricultural community: Just as different corn hybrids have distinct characteristics, cannabis terpenes create different sensory and potentially therapeutic experiences. The peppery notes of caryophyllene, the citrus brightness of limonene, the forest-fresh pinene—these aren’t just flavors; they’re part of the plant’s complex chemistry.

Evidence Standards Then and Now: Why This Matters for Iowa

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began in the early 2000s, cannabis was illegal in Canada and most of the world. There was no regulatory framework, no standardized testing, no legal pathway for clinical research, and no peer-reviewed journals dedicated to cannabis therapeutics. The underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected those constraints. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not a moral failing—it’s a description of his environment.

This document takes a fundamentally different approach. Our GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

We honor RSO’s historical origin while committing to modern cannabinoid science standards. Where Simpson relied on personal testimony, we rely on published literature and institutional sources.

Simpson’s Protocol vs. Modern Dosing: Why Louisa County Shouldn’t Follow the 60-Gram Protocol

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison to modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Key differences for Louisa County residents:

• Cannabinoid concentration: Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was ~60-90% delta-9 THC. Our formula distributes 16,590 mg total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence: Simpson’s oil had no terpenes. Our formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure: Simpson’s protocol at peak delivered ~600-900 mg delta-9 THC per day. Our sublingual formula contains only 90 mg delta-9 THC in the entire 30 mL bottle (3 mg/mL), making per-dose delta-9 THC exposure dramatically lower.

Bottom line for Louisa County: Do not follow Simpson’s 60-gram protocol with our product. Our dosing guidance is independent, informed by per-compound evidence in GENERAL KNOWLEDGE and responsible titration principles.

About OilWell Cannabis and Our RSO Formula

The Origin: From McAllen’s Border Danger to Houston’s Innovation Hub

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But Colin’s story begins in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. Reynosa is an industrial hub plagued by violence and cartel activity; McAllen is a city of contrasts—vibrant culture but limited opportunities outside retail and healthcare.

Colin’s childhood was marked by exposure to both opportunities and dangers. Early on, he learned to hustle, taking risky work transporting items across the border. He lost best friends to violence and prison. By sixteen, he had to leave home for good. He faced every form of violence imaginable, both in the streets and across the border.

Despite the dangers, Colin didn’t fall into selling harder substances. He focused on cannabis, seeing it as safer and more beneficial. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early ventures to creating a legal, legitimate business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine—one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

For Louisa County readers: Colin’s background isn’t corporate. It’s rooted in survival, community, and learning through hardship—values that resonate across Iowa’s farming communities. He understands what it means to build something from nothing, to face institutional barriers, and to create solutions when the system falls short.

Bentley’s Story: The Dog Who Started It All

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up wasn’t an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. He’d never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It wasn’t a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball. From paralyzed and facing euthanasia to fetching his ball. This was not placebo—dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia led him to CBC’s role in neurogenesis
• Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously

For Louisa County pet owners: We published Bentley’s exact CBD golden paste recipe on our website so any pet owner facing a similar crisis can make it themselves:

Bentley’s CBD Golden Paste Recipe:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size; consult a veterinarian)

Instructions: Mix turmeric and water in a saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add coconut oil and pepper. Cool and store in refrigerator up to two weeks. Mix small amount with pet’s food once or twice daily.

This recipe—published free, years before our RSO formulas—demonstrates that our open-source ethos isn’t marketing. It’s foundational behavior. Colin gave away the formula that saved Bentley before he gave away the formula for people.

Colin’s Personal Battle: PTSD, Benzo Addiction, and Peace Gummies

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer Peace Gummies in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For Louisa County veterans and trauma survivors: If you’re near the VA facilities in Iowa City or Rock Island, or working with Louisa County’s limited mental health resources, Colin’s experience shows that recovery is possible beyond pharmaceutical dependency. Our Peace Gummies—born from his withdrawal battle—are specifically formulated for PTSD, anxiety, and sleep disruption.

Doctors Use Our Formulas: Real Medical Integration

Over time, the therapeutic benefits Colin discovered through Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

We’ve worked with healthcare providers in the Texas Medical Center—the world’s largest medical complex with over 10 million patient visits annually—to integrate our products into patient care protocols. While we cannot name specific Iowa providers without their permission, the fact that medical professionals in Houston’s premier institutions trust our formulas speaks to the quality and precision of our work.

ABC13 Media Recognition: Houston’s Authority, Louisa County’s Assurance

Between September 2019 and April 2023, ABC13 Houston (KTRK) featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

Why This Matters for Louisa County: Mainstream media validation from a major-market ABC affiliate is credibility that transcends geography. When Wapello residents research our company, they’ll find seven documented instances where Houston’s #1 news source turned to us as the expert voice. That’s independent verification you can’t buy.

Complete ABC13 Feature Timeline:

1. Texas CBD businesses booming (September 15, 2019)
Reporter Tom Abrahams featured our origins. Colin’s quote became our philosophical foundation:

“I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

2. Entrepreneur creates direct-to-consumer business (March 22, 2021)
Abrahams returned as Colin helped other entrepreneurs enter legal cannabis. Colin’s therapy quote resonated deeply:

“Pain comes in a lot of different forms.”

3. What is Delta 8 THC (May 24, 2021)
Steve Campion’s investigative feature included Colin’s iconic honesty:

Campion: “Why would someone want to smoke that?”
Colin: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

4. Houston CBD shop giving away free products for COVID vaccine (August 20, 2021)
We gave away 1,000 caviar pre-rolls (~$35,000 in product) to encourage vaccination. We coordinated with the city of Houston, with no political strings attached—pure community health action.

5. Texas ban over Delta 8 (October 19, 2021)
When Texas DSHS classified Delta-8 as Schedule I overnight, Colin proactively removed all products before enforcement and warned other operators who were unknowingly shipping Schedule I narcotics. This ethical leadership during crisis defines our character.

6. Biden marijuana pardon—experts weigh in (October 7, 2022)
This feature revealed Colin’s personal marijuana conviction history:

“You face challenges with housing, loans, and banking, I mean with about everything.”
“I would love to see people not get hurt for this anymore.”

7. Marijuana industry getting creative (April 21, 2023)
Most recent feature, showing Colin growing hemp and framing the present as a “Renaissance” opportunity:

“Right now is actually a pretty—like Renaissance—pretty important time that should be enjoyed now.”

The Through-Line: These features show consistency across years, breadth of expertise, community action ($35K vaccine giveaway, Delta-8 proactive removal), personal stakes (conviction history), and evolution of language and role. This recognition cannot be purchased—it can only be earned.

OilWell Today: Licensed, Verified, Delivering to Louisa County

We operate from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Since 2019, we’ve generated approximately $1 million annual revenue, maintained a near-5.0 Google rating, and hold a Texas DSHS license. Our products aren’t mass-produced—they’re carefully crafted with personal touch, from artwork to formulations. All created in-house in Houston using only our own recipes and ideas.

For Louisa County: We’re not a faceless corporation. We’re a company built from real adversity, real love for a dog, real recovery from pharmaceutical dependency, and real commitment to community. We bring Houston grit and McAllen roots to everything we do, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy: Four Principles for Louisa County

Our RSO is not traditional Rick Simpson Oil. It’s a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it to solve problems that limited Simpson’s original vision.

1. Accessibility Over Gatekeeping

No medical card required. Anyone age 21+ can purchase. We ship nationwide across the United States and internationally to customers who verify local legality.

For Louisa County residents: Unlike Iowa’s limited medical cannabis program (TCUP) that requires qualifying conditions and physician certification, our products are accessible to any adult. Whether you’re in Wapello working the fields, in Morning Sun managing a small business, or in Columbus Junction dealing with chronic pain, you don’t need to prove a diagnosis to access our formulas. Simpson believed medicine should be accessible to everyone; we built a legal distribution model that makes that real.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency.

Louisa County application: Daytime functional use (raw) for farm work, operating equipment, or family responsibilities with zero impairment. Nighttime full-potency use (decarbed) for serious symptom relief. You control the decision through chemistry, not rhetoric.

3. Open-Source Formulas

We publish our complete formulas publicly—every cannabinoid, every milligram, every percentage—so anyone who cannot afford our products can source ingredients and make their own version.

For Louisa County’s economic reality: We understand that $129.99 for sublingual oil or $49.99 for a vape cartridge may be significant for families in Louisa County, where median household income is below state average. Our open-source ethos means you’re not shut out. If you have access to cannabinoid distillates, you can replicate our formula. This is our adaptation of Simpson’s free-distribution model for the modern marketplace.

4. Evidence-Informed, Not Evidence-Overstating

The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what science actually says. Simpson operated without peer-reviewed literature; we have that access and use it to distinguish between what’s well-supported, what’s emerging, and what’s overstated.

Farm Bill Compliance and the THCa Legal Framework: What Louisa County Needs to Know

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle—3 mg per mL—well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Iowa.

THCa Legal Distinction: THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

Practical Significance for Louisa County:
You can legally purchase, possess, and transport our product. Decarboxylation—heating oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container—converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with existing 90 mg delta-9 THC, this yields ~1,405 mg total delta-9 THC, giving you psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

Important Legal Notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Iowa state and Louisa County local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis (COAs), and receipts. International customers accept all customs and legal responsibility.

For Iowa specifically: Iowa law aligns with the Farm Bill regarding hemp-derived products with <0.3% delta-9 THC. Our products are legal to ship to Louisa County. However, be aware that workplace drug testing policies in Iowa (including at local employers like the schools, government offices, or agricultural operations) may still penalize THC metabolites regardless of source. We’re honest about this: if you decarboxylate and use the psychoactive form, you will likely test positive. If you use raw THCa, you likely won’t. Make informed decisions based on your employment situation.

The Decarboxylation Choice: Three Options for Louisa County Residents

Traditional RSO was always fully decarboxylated. Our sublingual formula contains 1,500 mg THCa in acidic, non-psychoactive form, creating three distinct usage options:

Option 1—Raw, No Heat: All 1,500 mg stays as THCa—completely non-psychoactive. THCa evidence shows potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This is compatible with operating tractors, handling livestock, driving to Muscatine for supplies, or any daytime Louisa County activity with zero impairment.

Option 2—Fully Activated, Home Decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC—psychoactive potency comparable to traditional illegal RSO, 100% legally, because decarboxylation occurs at your discretion after purchase. You can also transfer a controlled portion to a second container, decarboxylating only what you intend to use while preserving remainder in raw THCa form.

Option 3—Vape, Auto-Decarboxylation: Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method—ideal for breakthrough pain or acute anxiety episodes.

Conversion Chemistry: THCa has molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

Solvent-Free Production: Safety You Can Verify

Our RSO is not a traditional extraction product. It’s a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents in finished product.

This eliminates residual solvent risk—one of the most significant safety concerns with traditional RSO production, especially relevant for Louisa County residents who may have encountered contaminated products or lack access to professional testing.

Organic MCT Oil Base: We use food-grade medium-chain triglycerides as carrier oil, facilitating cannabinoid absorption through sublingual tissue and providing neutral taste—major improvement over traditional RSO’s tar-like consistency and solvent-residual odor.

Third-Party Lab Testing: Every batch undergoes comprehensive testing covering:

• Cannabinoid potency (HPLC/UHPLC analysis, ±2% accuracy)
• Terpene profile
• Pesticides (400+ compound screening via LC-MS/MS and GC-MS/MS)
• Heavy metals (arsenic, cadmium, lead, mercury below FDA limits via ICP-MS)
• Residual solvents (FDA Class 3 limits <5,000 ppm via headspace GC)
• Microbial contaminants (E. coli, Salmonella, Aspergillus screening)

Certificates of Analysis (COAs) are available on request and accessible through our website. For Louisa County customers, we provide COAs with every shipment—transparency you can verify.

The Broader OilWell Product Portfolio: Beyond RSO

Beyond our flagship RSO, we produce several cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own PTSD/benzo withdrawal experience.

Asshole Peach—$39.99: Our most popular product. Carefully formulated for euphoric, long-lasting sensation. Particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive.

Peace Gummies—$34.99: Born directly from Colin’s PTSD and benzodiazepine addiction experience. Helped him quit Xanax cold turkey. Available in vape form for quick relief—Colin personally uses it to manage his insomnia and severe PTSD.

SWEETEMintz Sugar-Free Vegan Peppermint Hard Candy—$39.99: 28 mg Delta-9 Nano THC, 100 mg Nano CBD, 50 mg CBG Isolate. Zero sugar, 100% vegan—designed for diabetic and health-conscious consumers.

Custom Creations: We design tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances—including formulations for vegans, diabetics, and those with specific dietary needs.

Two Product Formats for Louisa County Needs

We offer our RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

Specifications:

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg/mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

For Louisa County: This is your daily workhorse for sustained relief. Whether managing chronic pain from years of physical labor, supporting sleep through Iowa’s cold winters, or addressing anxiety while maintaining family responsibilities, the sublingual oil provides controlled, measurable dosing.

RSO Vape Cartridge—$49.99

Specifications:

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable by inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

For Louisa County: This is your breakthrough tool. When pain spikes unexpectedly, when anxiety overwhelms, when nausea hits hard—the vape provides near-instant relief. Compact enough to carry while running errands in Wapello or working in the fields.

When to Use Each Format in Louisa County

Use Case	Recommended Format	Why It Works for Louisa County
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset when you’re in the middle of a task and can’t wait
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration gets you through a full morning of chores or a full night’s rest
Maximum bioavailability	Sublingual	13-19% absorption efficiency means more medicine reaches your system
Portability/discretion	Vape	Compact, no measuring—easy to carry to the Louisa County Fair or community events
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments for exact titration
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive—zero impairment while operating equipment or driving County Road 99
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for serious symptom relief after the day is done

Competitive Comparison: Why OilWell is Different for Louisa County

OilWell RSO vs. Iowa’s Medical Cannabis Program (TCUP)

Iowa’s Therapeutic Cannabis Program (TCUP) is highly restrictive. To access TCUP dispensary RSO, you need:

• Qualifying condition (cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases)
• Physician certification
• Registration card
• Must travel to one of few dispensaries (none in Louisa County—nearest are in Des Moines or Davenport)

OilWell RSO advantages for Louisa County:

• No qualifying condition needed: Any adult 21+ can purchase
• No physician certification: No need to find a cannabis-friendly doctor in rural Iowa
• No registration: No state database, no annual fees
• Ships directly to Louisa County: No 50-mile drive to Davenport—delivered to your door
• Multi-cannabinoid vs. THC-only: TCUP RSO is approximately THC-only. Our formula includes seven cannabinoids
• Patient-controlled potency: TCUP products are fully psychoactive. You control whether ours is psychoactive
• Farm Bill compliant: Legal under federal law; TCUP operates under state medical program

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg (~1,315 mg delta-9 THC when decarbed)
Psychoactive option	No meaningful effect	Yes—via THCa decarboxylation and delta-8 THC
Price	$40-50	$129.99

For Louisa County: You’re getting 16.5x more total cannabinoids, with a complete multi-cannabinoid profile, for roughly 2.5x the price—substantially better value per milligram of active compound.

OilWell RSO vs. Traditional Illegal RSO

(See comparison table in “Traditional RSO vs. Modern Formulated RSO” section)

Condition-Specific Usage Context for Louisa County

Important Disclaimer: These usage contexts are informed by cannabinoid research cited in GENERAL KNOWLEDGE and our formulation rationale. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT substitutes for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

For Louisa County residents traveling to University of Iowa Holden Comprehensive Cancer Center or Genesis Cancer Care Institute for treatment:

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

For Louisa County’s agricultural workers, manufacturing employees, and aging population:

• Daytime: 0.3-0.5 mL raw sublingual—anti-inflammatory cannabinoid exposure without psychoactive impairment, safe for operating equipment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

For Louisa County residents struggling with insomnia, whether from pain, PTSD, or stress:

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN—dosage level investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN—above threshold associated with reduced sleep disturbance

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and Stress

For Louisa County residents managing rural isolation, economic stress, or family pressures:

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General Titration Principle for Louisa County: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. If you’re new to cannabinoids, take your first doses on a weekend or evening when you don’t have work responsibilities.

Delivery and Global Accessibility: Getting OilWell RSO to Louisa County

Shipping to Louisa County, Iowa

While we operate same-day delivery in Houston, for Louisa County we provide fast, reliable shipping throughout Iowa and the Midwest.

Nationwide Shipping to Louisa County:

• USPS Priority Mail: 2-3 business days to Wapello, Morning Sun, Columbus Junction, or any Louisa County address
• FedEx/UPS Ground: 3-5 business days
• Discreet packaging: No cannabis branding visible on exterior
• Tracking: Provided for all orders
• Temperature-stable packaging: Iowa summers can be hot; our packaging protects product integrity
• Signature-required option: Available if you prefer

For Iowa: Our products are Farm Bill compliant and legal to ship to Louisa County. We include complete documentation and COAs with every package in case questions arise with local law enforcement (though this is unlikely given compliance).

International Shipping: We ship worldwide. While Louisa County residents likely don’t need this, it demonstrates our product’s legal portability—something Rick Simpson could never achieve with his illegal oil.

Contact: (832) 416-2816 or [email protected]

How Our Formulas Connect to the Evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in our GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

Our published formulas are anchored to per-compound evidence summaries explaining what’s well-supported by human clinical data, what’s emerging, and what’s overstated. Where our RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides source evaluation context—the same peer-reviewed citations, evidence-tier assessments, and cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. That is intentional. Our position—stated by Colin in 2019—is that people deserve the best possible version of information so they can give it a fair shot and decide for themselves whether it’s right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand—it’s a promise to customers that we will always strive to deliver the best, most thoughtful cannabis products available. We’re not here to follow trends. We’re here to set them. As we continue to grow, our focus remains on maintaining the same integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

GENERAL KNOWLEDGE: The Science Behind Every Compound

Research Method and Evidence Weighting

This section prioritizes sources in order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic/preclinical literature when human data are sparse. This matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, or early translational literature [1]-[29].

Institutional Baseline: What NIH and FDA Say

• NCCIH states: Strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications in HIV/AIDS. Modest evidence for chronic pain and MS-related symptoms. Many claimed uses remain early-stage [1].
• FDA position: Has not approved cannabis plant itself for medical use. Only purified CBD (Epidiolex for seizures) and synthetic THC-like drugs (dronabinol/nabilone for chemo nausea and AIDS wasting) have specific approvals [1].
• Safety concerns: Impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, labeling inaccuracy, THC-vape lung injury [1].
• NCCIH warnings: Over-the-counter CBD products may differ from labels. CBD associated with decreased alertness, GI effects, liver adverse effects, drug interactions [1].

Cannabinoid Evidence Profiles

CBD

• Strongest evidence: Seizure disorders (human clinical trials) [1][2]
• Anxiety: 2024 meta-analysis of 316 participants showed significant anxiolytic signal but authors stress limited clinical sample, more trials needed [3]
• Pain: 2024 review concluded promising but heterogeneous, trial quality limiting confidence [4]
• Sleep: 2023 review found literature methodologically weak, few objective assessments [5]
• Safety: 2023 meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy [6]
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in few specific indications, not broad wellness claims [1]-[6]

CBG

• Evidence: Mostly review-level and preclinical; human evidence sparse [7][8]
• Pharmacology: Biosynthetic precursor to major cannabinoids; interacts with cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling—mechanistically interesting but not clinically established [7]
• Research areas: Possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity—primarily pharmacology-led hypotheses or preclinical [7][8]
• Caution: 2021 review notes CBG is sold commercially while evidence base remains thin—claims frequently outrun science [7]
• Bottom line: Serious research topic but should be described as promising minor cannabinoid with limited clinical validation [7][8]

Delta-8 THC

• Evidence: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11]
• Comparative pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar pharmacokinetic/pharmacodynamic behavior. Delta-8 is partial CB1 agonist, less potent than delta-9, likely due to weaker CB1 affinity [9]
• Public-health literature: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, public-health concerns rather than strong human trials. Noted reports of adverse consequences, regulatory and product-quality concerns [10]
• Manufacturing: 2024 chemistry review notes commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels—product-byproduct and lab-testing questions matter [11]
• Bottom line: Should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11]

THCa

• Evidence: Important chemically/formulation-wise, but low on direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC; may represent large share of THC-related content in raw plant. Decarboxylates to THC during heating, can change over time during storage/processing [12]
• Psychoactivity: THCa itself does not produce psychoactive effects associated with THC, but distinction only holds if molecule stays acidic and is not substantially decarboxylated [12]
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities, but not equivalent to established human outcomes [12]
• Bottom line: Best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, storage. Any claim about THCa must account for possible conversion to THC [12]

Delta-9 THC

• Evidence: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15]
• Institutionally supported: NCCIH identifies relevance to chemo-related nausea/vomiting, appetite/weight loss in HIV/AIDS, some MS- and pain-related outcomes, while stressing many other uses remain uncertain/early-stage [1]
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found high-THC products may provide short-term benefit but also increased dizziness, sedation, nausea, treatment discontinuation due to adverse events [13]
• Pharmacokinetics: Classic review literature—inhale: effects within seconds-minutes, peak 15-30 minutes, taper over few hours; oral: later onset, later peak, longer duration—matters for both benefit and overconsumption risk [14]
• Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, plus concerning signals for anxiety/depression in nontherapeutic settings [15]
• Broader safety: Anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung injury [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15]

CBN

• Evidence: Weak human evidence; marketing has clearly moved ahead of data [12][16][17]
• What marketed for: Sleep and sedation. Reputation widespread but clinical support far thinner than market suggests [16][17]
• Best sleep evidence review: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated review concluded overall cannabinoid sleep research still doesn’t match scale of real-world use, need for better-designed, adequately powered trials remains substantial [17]
• Chemical context: Review literature on THCa notes THC can degrade toward CBN under certain conditions, helping explain why CBN often discussed in aging/oxidized cannabis chemistry contexts [12]
• Bottom line: One of clearest examples where cultural reputation stronger than current clinical evidence base [16][17]

CBC

• Evidence: Emerging, intriguing, still overwhelmingly preclinical or review-based [18][19]
• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, receptor behavior relative to better-known cannabinoids, highlights antinociceptive, antibacterial, anti-seizure areas as especially interesting research targets [18]
• Older literature: Review literature summarizing CBC in animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological/antiproliferative relevance, but not yet strong evidence for patient-facing claims [19]
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already being sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: Belongs in category of scientifically credible minor cannabinoids deserving more research, not category of already-validated clinical actives [18][19]

Terpene Evidence Profiles

Terpene claims need stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence: Largely review and preclinical, with useful safety literature [20]-[22]
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share of claims from nonhuman/non-cannabis literature [21]
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22]
• Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22]

Myrcene

• Evidence: Mostly preclinical, very limited human evidence [20][23]
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and discusses possible mechanisms, but explicitly states human studies lacking [23]
• Interpretation caution: Myrcene often invoked in consumer language as proven sedating terpene explaining couch-lock or sleep effects. Stronger claim than human evidence currently supports [20][23]
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive human proof [23]

Caryophyllene

• Evidence: Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24]
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist—unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation limited [24]
• Bottom line: Arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24]

Pinene

• Evidence: Promising preclinical literature, weak human clinical confirmation [20][25]
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence mostly preclinical and well-designed clinical trials lacking [25]
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25]

Linalool

• Evidence: Similar to pinene—substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research summary: Linalool repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while still emphasizing lack of robust human trials [25]
• Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26]
• Safety note: As with limonene, oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22]
• Bottom line: Scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Evidence: Translationally interesting, but still early [20][27]
• Scoping-review findings: 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27]
• Bottom line: One of more interesting terpene research targets in this list, but remains far from clinically settled [27]

Terpinolene

• Evidence: One of least clinically characterized terpenes in this file [20][28]
• Systematic-review findings: 2021 terpinolene review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28]
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20]
• Bottom line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28]

Research Limits and Interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29]
• Extract/molecule/synthetic/terpene data aren’t interchangeable. Common error: letting evidence from one category stand in for another
• Minor cannabinoids and terpenes commercially interesting precisely because underexplored, but that also means claims often become inflated
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability all materially affect interpretation in real-world products [1][10][11][14]
• THCa chemistry is destiny: Storage and heating can change actual exposure profile by converting acidic cannabinoids to neutral cannabinoids like THC [12]

Common Overstatements to Avoid (What Competitors Get Wrong)

Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].

Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for common claim is limited [20][23].

Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa to THC, changing effective exposure [12].

Overstatement: Delta-8 THC is safe because it is hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for Louisa County

• Most evidence-developed actives in these formulas: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild; it is psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing; should not be interpreted same way in raw, gently handled, and heated formats
• CBG, CBN, CBC scientifically credible but clinically immature compared with CBD and THC
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

RSO Sublingual Oil Formula

Cannabinoid Profile:

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

Additional Specifications:

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper in 0.1 mL increments
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%

RSO Vape Cartridge Formula

Cannabinoid Profile:

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

Additional Specifications:

• Live Terpenes: 5%
• Format: 1 Gram cartridge
• Compatibility: 510-thread universal battery
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

Terpene Profile (Both Products)

Seven Live Terpenes:

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

Sensory Experience: When you open a bottle of our sublingual oil in your Louisa County kitchen, you’ll notice complex aromas—citrus brightness from limonene, peppery notes from caryophyllene, forest-fresh pinene. This isn’t just flavor; it’s the entourage effect in action.

Condition-Specific Resources for Louisa County

Cancer Support:

• University of Iowa Holden Comprehensive Cancer Center (Iowa City) – ~50 miles
• Genesis Cancer Care Institute (Davenport) – ~40 miles
• American Cancer Society Eastern Iowa Chapter – resources for Louisa County patients
• Louisa County caregivers’ support networks (contact local churches/community centers)

Veteran Support:

• VA Iowa City Health Care System
• Rock Island Arsenal VA Clinic (Illinois)
• Louisa County Veteran Affairs Office (Wapello)
• PTSD support groups through Iowa Veterans Affairs

Chronic Pain & Arthritis:

• Genesis Health System Pain Management (Davenport)
• University of Iowa Pain Management Clinic
• Louisa County Public Health nursing consultations

Mental Health & Addiction:

• Louisa County Mental Health Services (Wapello)
• Southeast Iowa Behavioral Health (West Burlington)
• Iowa Department of Public Health addiction resources

Legal Questions:

• Iowa Department of Public Health – Medical Cannabidiol Program
• Iowa Attorney General’s Office – hemp product regulations
• Louisa County Sheriff’s Office – local enforcement policies

Final Thoughts for Louisa County

We’ve built this guide because people in Louisa County deserve what everyone deserves: honest information about cannabis medicine, grounded in real science, delivered by people who’ve lived the struggle. From Colin’s childhood in one of America’s most dangerous border regions to Bentley’s miraculous recovery to Colin’s own battle with benzo addiction—every word here comes from experience, not theory.

Our products are not magic bullets. They won’t cure cancer. They won’t fix every problem. But for many people dealing with chronic pain, PTSD, sleep disorders, chemotherapy side effects, or the hell of benzodiazepine withdrawal, they offer something pharmaceutical medicine often can’t: a chance to reclaim autonomy over your own healing.

For Louisa County residents ready to try: Order online at oilwellcbd.com. We’ll ship directly to your door in Wapello, Morning Sun, Columbus Junction, or anywhere in the county. Your package will arrive discreetly, with full lab documentation, within 2-3 days. If you have questions, call us at (832) 416-2816. We’re real people who answer the phone.

For Louisa County residents who can’t afford our products: Use our open-source formulas. Source the ingredients. Make your own. The recipes are yours. That’s how Colin saved Bentley, and that’s how we honor Rick Simpson’s original vision of free access.

For Louisa County residents with doubts: Good. Be skeptical. Read the science in our GENERAL KNOWLEDGE section. Check our COAs. Verify our media coverage. Talk to your doctor. Make an informed decision. We’re not here to pressure you—we’re here to educate you.

The Mississippi River flows past Louisa County bringing change and continuity. The corn fields cycle through planting and harvest. And somewhere in Houston, a man who lost friends to border violence and saved his dog with cannabinoids is still formulating, still testing, still refusing to sell snake oil.

That’s OilWell Cannabis. That’s what we offer Louisa County. And that’s why this guide exists.

References

Rick Simpson Section:
RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

General Knowledge Section:

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

Contact and Ordering Information for Louisa County

OilWell Cannabis
810 Richmond Avenue, Houston, TX 77006
Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/

RSO Sublingual Oil: https://oilwellcbd.com/product/rick-simpson-oil-rso-sublingual-oil/
RSO Vape Cartridge: https://oilwellcbd.com/product/1-gram-rick-simpson-oil-rso-vape/
Complete RSO Guide: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Instagram: @oilwellcbd
Hours: Monday-Thursday 10 AM-7 PM, Friday-Saturday 10 AM-10 PM, Sunday 10 AM-4 PM (Central Time)

Shipping to Louisa County: All orders ship within 24 hours. Iowa residents typically receive packages in 2-3 business days via USPS Priority Mail.

For Louisa County questions: Call (832) 416-2816. We’re here to help you understand the science, choose the right product, and use it safely and effectively.